RxDoctor Payments Data

Nikia Bennett

Physician Assistant · Poughkeepsie, NYNPI 1518694827

Payments from drug & device makers

$900in general payments, 2019–2025

Across 28 payments — averaging $32.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$239
  • Tolmar, Inc.$173
  • Medical Device Business Services, Inc.$137
  • AbbVie$59
  • Astellas Pharma US Inc$32
  • Progenics Pharmaceuticals, Inc.$30
  • plus $230 from 11 others

What the payments were for

  • Travel & lodging$13915%
  • Food & beverage$52458%
  • Education$23726%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$900 in reported general payments places this provider in the 70th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Medicare billing

Part B allowed, 2024
$24,524
Medicare patients
216
Services billed
598

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron67$39,598
MyrbetriqMirabegron32$17,653
Estradiol45$3,641
Tamsulosin Hcl241$3,425
Finasteride94$1,279
Alfuzosin Hcl ErAlfuzosin Hcl42$700
NitrofurantoinNitrofurantoin Macrocrystal20$572
Dutasteride16$493
Oxybutynin Chloride ErOxybutynin Chloride17$461
Solifenacin Succinate17$401
Oxybutynin Chloride15$329
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip12$272
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim57$231
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst17$213
CefuroximeCefuroxime Axetil24$206

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$20$39,59867 claims
Astellas Pharma US IncMyrbetriq$32$17,65332 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in Poughkeepsie

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →